The Trip Report by Beckley Waves

Home
Archive
About
NewTopDiscussion
Neither Cannabis 2.0 nor Drug Development…but a Third, More Complex Thing
Zach Haigney
The Long Shadow of MAPS; Ups and Downs of a Retail Investor Base; Safety Four Ways
Zach Haigney
1
“If the hyper-intelligent AI is not filled with bodhisattva compassion, then our ass is probably grass.” —Terrence Mckenna In the summer of 1956…
Zach Haigney
1
This week we’re looking at a few developments that occupy what we might call the “infrastructure and operational” layer required for…
Zach Haigney
Welcome back to The Trip Report by Beckley Waves—after several weeks of sound rest school vacation, we’re ready for a big year in the psychedelic…
Zach Haigney
Hello! On the occasion of my recent appearance on the Business Trip Podcast, where I spoke with Greg Kubin of the Psychedelic Medicine Syndicate, I…
Zach Haigney
In a recent interview with The Microdose, Raquel Bennett, the founder of the Ketamine Research Institute and an expert on the therapeutic use—and…
Zach Haigney
Greetings friends, I hope this dispatch—the last of 2022!—finds you well and heading into restful days. I, for one, am excited to take a break…
Zach Haigney
1
Part 1: Direct-to-Consumer healthcare & Decentralized Clinics
Zach Haigney
Today, we’re looking at developments from the European Union and changes to the laws governing the telehealth prescribing of ketamine. But first, a…
Zach Haigney
The news from psychedelia is starting to trickle (thank god!) as we head into year’s end and approach 2023, a pivotal year for psychedelic policy and…
Zach Haigney
This week we’re looking at: The results and implications of the first controlled trial of psilocybin-assisted therapy for heavy drinking Recent findings…
Zach Haigney
1
© 2023 Zach Haigney
Privacy ∙ Terms ∙ Collection notice
Start WritingGet the app
Substack is the home for great writing